|
1
|
Guturu P and Duchini A: Etiopathogenesis
of nonalcoholic steatohepatitis: Role of obesity, insulin
resistance and mechanisms of hepatotoxicity. Int J Hepatol.
2012:2128652012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bala C, Crăciun AE and Hâncu N: Updating
the concept of metabolically healthy obesity. Acta Endo.
12:197–205. 2016. View Article : Google Scholar
|
|
3
|
Badiu C: Endocrine management in
Prader-Willi Syndrome. Acta Endo. 8:99–106. 2012. View Article : Google Scholar
|
|
4
|
Ianoşi S, Ianoşi G, Neagoe D, Ionescu O,
Zlatian O, Docea AO, Badiu C, Sifaki M, Tsoukalas D, Tsatsakis AM,
et al: Age-dependent endocrine disorders involved in the
pathogenesis of refractory acne in women. Mol Med Rep.
14:5501–5506. 2016.PubMed/NCBI
|
|
5
|
Rehm JL, Connor EL and Reeder SB:
Non-alcoholic fatty liver disease in an adolescent with polycystic
ovary syndrome. J Pediatr Adolesc Gynecol. 24:e61–e66. 2011.
View Article : Google Scholar
|
|
6
|
Arciello M, Gori M, Maggio R, Barbaro B,
Tarocchi M, Galli A and Balsano C: Environmental pollution: A
tangible risk for NAFLD pathogenesis. Int J Mol Sci.
14:22052–22066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hernández AF, Gil F, Lacasaña M,
Rodríguez-Barranco M, Tsatsakis AM, Requena M, Parrón T and Alarcón
R: Pesticide exposure and genetic variation in
xenobiotic-metabolizing enzymes interact to induce biochemical
liver damage. Food Chem Toxicol. 61:144–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsitsimpikou C, Tzatzarakis M, Fragkiadaki
P, Kovatsi L, Stivaktakis P, Kalogeraki A, Kouretas D and Tsatsakis
AM: Histopathological lesions, oxidative stress and genotoxic
effects in liver and kidneys following long term exposure of
rabbits to diazinon and propoxur. Toxicology. 307:109–114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duan XY, Zhang L, Fan JG and Qiao L: NAFLD
leads to liver cancer: do we have sufficient evidence? Cancer Lett.
345:230–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baffy G, Brunt EM and Caldwell SH:
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an
emerging menace. J Hepatol. 56:1384–1391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marconi A, Candido S, Talamini R, Libra M,
Nicoletti F, Spandidos DA, Stivala F and Proietti L: Prevalence of
hepatitis C virus infection among health-care workers: A 10-year
survey. Mol Med Rep. 3:561–564. 2010.PubMed/NCBI
|
|
12
|
Docea AO, Gofiță E, Călina D, Zaharie SI,
Vâlcea DI and Mitruț P: Autoimmune disorders due to double
antiviral therapy with Peginterferon and Ribavirin in patients with
hepatitis C virus infection. Farmacia. 64:605–611. 2016.
|
|
13
|
Chitturi S, Farrell GC, Hashimoto E,
Saibara T, Lau GK and Sollano JD: Asia-Pacific Working Party on
NAFLD: Non-alcoholic fatty liver disease in the Asia-Pacific
region: Definitions and overview of proposed guidelines. J
Gastroenterol Hepatol. 22:778–787. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lizardi-Cervera J and Aguilar-Zapata D:
Nonalcoholic fatty liver disease and its association with
cardiovascular disease. Ann Hepatol. 8 Suppl 1:S40–S43.
2009.PubMed/NCBI
|
|
15
|
Almeda-Valdés P, Cuevas-Ramos D and
Aguilar-Salinas CA: Metabolic syndrome and non-alcoholic fatty
liver disease. Ann Hepatol. 8:S18–S24. 2009.PubMed/NCBI
|
|
16
|
Centers for Disease Control and
Prevention: Behavioral Risk Factor Surveillance System. National
Center for Chronic Disease Prevention and Health Promotion,
Division of Population Health; Atlanta, GA: 2014, http://apps.nccd.cdc.gov/brfss/index.asp
|
|
17
|
Kleiner DE, Brunt EM, van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, et al: Nonalcoholic Steatohepatitis Clinical
Research Network: Design and validation of a histological scoring
system for nonalcoholic fatty liver disease. Hepatology.
41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taylor F, Ward K, Moore TH, Burke M, Smith
G Davey, Casas JP and Ebrahim S: Statins for the primary prevention
of cardiovascular disease. Cochrane Database Syst Rev.
19:CD0048162011.
|
|
19
|
Kiyici M, Gulten M, Gurel S, Nak SG, Dolar
E, Savci G, Adim SB, Yerci O and Memik F: Ursodeoxycholic acid and
atorvastatin in the treatment of nonalcoholic steatohepatitis. Can
J Gastroenterol. 17:713–718. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Balistreri WF: Nonalcoholic fatty liver
disease - insights and controversies. CME Digestive Disease Week.
Medscape. 2006.
|
|
21
|
Foster T, Budoff MJ, Saab S, Ahmadi N,
Gordon C and Guerci AD: Atorvastatin and antioxidants for the
treatment of nonalcoholic fatty liver disease: The St Francis Heart
Study randomized clinical trial. Am J Gastroenterol. 106:71–77.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gómez-Domínguez E, Gisbert JP,
Moreno-Monteagudo JA, García-Buey L and Moreno-Otero R: A pilot
study of atorvastatin treatment in dyslipemid, non-alcoholic fatty
liver patients. Aliment Pharmacol Ther. 23:1643–1647. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chitturi S and Farrell GC: TNF-alpha as
therapeutic target in NASH: Tried, but not yet proven. J
Gastroenterol Hepatol. 22:613–614. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Satapathy SK, Garg S, Chauhan R, Sakhuja
P, Malhotra V, Sharma BC and Sarin SK: Beneficial effects of tumor
necrosis factor-alpha inhibition by pentoxifylline on clinical,
biochemical, and metabolic parameters of patients with nonalcoholic
steatohepatitis. Am J Gastroenterol. 99:1946–1952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Satapathy SK, Sakhuja P, Malhotra V,
Sharma BC and Sarin SK: Beneficial effects of pentoxifylline on
hepatic steatosis, fibrosis and necroinflammation in patients with
non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 22:634–638.
2007.PubMed/NCBI
|
|
26
|
Zein CO, Yerian LM, Gogate P, Lopez R,
Kirwan JP, Feldstein AE and McCullough AJ: Pentoxifylline improves
nonalcoholic steatohepatitis: A randomized placebo-controlled
trial. Hepatology. 54:1610–1619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Van Wagner LB, Koppe SW, Brunt EM,
Gottstein J, Gardikiotes K, Green RM and Rinella ME: Pentoxifylline
for the treatment of non-alcoholic steatohepatitis: A randomized
controlled trial. Ann Hepatol. 10:277–286. 2011.PubMed/NCBI
|
|
28
|
Adams LA, Zein CO, Angulo P and Lindor KD:
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am
J Gastroenterol. 99:2365–2368. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Comar KM and Sterling RK: Review article:
Drug therapy for non-alcoholic fatty liver disease. Aliment
Pharmacol Ther. 23:207–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Neuner P, Klosner G, Schauer E, Pourmojib
M, Macheiner W, Grünwald C, Knobler R, Schwarz A, Luger TA and
Schwarz T: Pentoxifylline in vivo down-regulates the release of
IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human
peripheral blood mononuclear cells. Immunology. 83:262–267.
1994.PubMed/NCBI
|
|
31
|
Warne JP: Tumour necrosis factor alpha: A
key regulator of adipose tissue mass. J Endocrinol. 177:351–355.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wigg AJ, Roberts-Thomson IC, Dymock RB,
McCarthy PJ, Grose RH and Cummins AG: The role of small intestinal
bacterial overgrowth, intestinal permeability, endotoxaemia, and
tumour necrosis factor alpha in the pathogenesis of non-alcoholic
steatohepatitis. Gut. 48:206–211. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ungureanu A, Gaman AE, Drocas AI, Tieranu
E and Dobrițoiu M: The influence of steatosis and conjugate factors
of response to antiviral treatment in cronic hepatitis C, The null.
Research and Science Today. 11:147–155. 2016.
|
